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Complementary medicine — Research
medicines and aromatherapy products.
CAM practices include a diverse group of
therapies such as herbal medicine, chiro-
practic, osteopathy, naturopathy, homeopa-
thy and acupuncture. In the United States,









Objective:  To survey the use, cost, beliefs and quality of life of users of complementary 
and alternative medicine (CAM).
Design:  A representative population survey conducted in 2004 with longitudinal 
comparison to similar 1993 and 2000 surveys.
Participants:  3015 South Australian respondents over the age of 15 years (71.7% 
cipation).
lts:  In 2004, CAMs were used by 52.2% of the population. Greatest use was in 
en aged 25–34 years, with higher income and education levels. CAM therapists had 
 visited by 26.5% of the population. In those with children, 29.9% administered 
s to them and 17.5% of the children had visited CAM therapists. The total 
polated cost in Australia of CAMs and CAM therapists in 2004 was AUD$1.8 billion, 
 was a decrease from AUD$2.3 billion in 2000. CAMs were used mostly to maintain 
general health. The users of CAM had lower quality-of-life scores than non-users. 
Among CAM users, 49.7% used conventional medicines on the same day and 57.2% did 
not report the use of CAMs to their doctor. About half of the respondents assumed that 
CAMs were independently tested by a government agency; of these, 74.8% believed 
they were tested for quality and safety, 21.8% for what they claimed, and 17.9% for 
efficacy.
Conclusions:  Australians continue to use high levels of CAMs and CAM therapists. 
The public is often unaware that CAMs are not tested by the Therapeutic Goods 
MJA 2006; 184: 27–31
Administration for efficacy or safety.on
co
is N -representative surveys in manyuntries have suggested that therea high use of complementary and
alternative medicine (CAM). CAMs include
herbal medicines, traditional medicines
(Ayurvedic or Chinese), vitamin, mineral
and nutritional supplements, homeopathic
In Australia, we previously conducted
two representative population surveys in
South Australia examining the use and cost
of CAMs, using the South Australian Health
Omnibus Surveys. We found that, between
1995 and 2000, there had been an increase
in the use of CAMs and over-the-counter
medicines.2,3
In 2004, we conducted a third representa-
tive population survey in South Australia,
surveying the trend in CAM use since the
Pan Pharmaceutical crisis (in which a sub-
stantial quantity of CAM products was
removed from retail stores) and asking fur-
ther questions about the public’s beliefs
concerning the CAMs and their quality of
life.
METHODS
Data were collected via the South Australian
Health Omnibus Survey conducted in
March–April 2004. The Health Omnibus
Survey is a large representative population
survey that has been undertaken annually in
South Australia since 1990 using a clus-
tered, multistage, systematic, random, self-
weighting area sample. Weighting ensures
that every household has the same probabil-
ity of being selected. This approach has been
used consistently from the inception of the
survey and involves sampling people aged
15 years and over living in metropolitan
Adelaide and major country towns with a
population exceeding 1000.4 South Aus-
tralia has a slightly older population on
average than other Australian states, but
otherwise the population is generally similar
to Australian demographic data.
The survey data were weighted to the
2002 Australian Bureau of Statistics Esti-
mated Residential Population data by sex, 5-
year age groups and geographic area so that
the findings apply to the demographic pro-
file of South Australia. To estimate reliability,
10% of the respondents were resurveyed.
Age, sex, marital status, education,
employment status, area of residence, coun-
try of birth, and household income level
were recorded.
The respondents were given the following
definition:
The following questions are about com-
plementary and alternative medicines,
including over-the-counter medicines,
alternative therapies or remedies and
herbal medicine.
They were asked whether they had used
any complementary or alternative medicines
or health products over the past year, with
seven main types listed on a prompt card
with samples of each type (herbal medicines,
vitamins, mineral supplements, Chinese medi-
cines, homeopathic medicines, soy products,
aromatherapy oils, other or none). Excluded
were calcium, iron or vitamins prescribed by
a medical practitioner. The respondents
were asked to estimate, to the nearest dollar,
the monthly cost of these products.
A prompt card was used to seek the main
reasons for the use of these medicines, with
the categories general health; blood or circula-
tion; bladder or kidneys; muscles, bones or
joints; lungs or sinuses; immune system; nerves
or stress; stomach and bowels; prostate; PMS/
menopause; skin; other; and don’t know.JA • Volume 184 Number 1 • 2 January 2006 27
COMPLEMENTARY MED ICINE —  R ESEARCHRespondents were asked if their medical
practitioner knew about the complementary
medicines being taken and whether they
used these medicines on the same day that
they took conventional medicines.
They were also asked if they had visited
any of the following therapists listed on a
prompt card in the last year: herbal therapist/
herbalist; naturopath/natural therapist; aroma-
therapist; homeopath; acupuncturist; iridolo-
gist; osteopath; chiropractor; reflexologist;
other; none; and don’t know. The approximate
total yearly cost of these therapists (not
including the cost of any medicine they
prescribed or sold) was asked.
Respondents were asked if any children in
their household were ever given CAM medi-
cines or therapies with the following
options: no children in household; children but
alternative medicine and therapies not used; yes
— non-prescribed vitamins; yes — other alter-
native medicines/products; yes — therapists
listed on the above prompt card; other alterna-
tive therapists; and don’t know.
Respondents were asked: “Do you think
that complementary or alternative medi-
cines are independently tested by a govern-
ment agency such as the Therapeutic Goods
Administration before being sold?” and
“What do you think they are tested for?”.
Possible answers were quality/safety/side
effects; efficacy/strength/effect; that they do
what they claim to do; other; and don’t know.
Similar questions, but not all, had been
asked using the same method in surveys of
the same population in 1993 and 2000.2,3
Where possible, the answers to the same
questions were compared between surveys.
The data were analysed using SPSS ver-
sion 12.0 (SPSS Inc, Chicago, Ill, USA) and
Epi Info version 6.04 (Centers for Disease
Control and Prevention, Atlanta, Ga, USA).
All cost data were adjusted using the con-
sumer price index.
The South Australian Health Omnibus
Advisory Committee independently vetted




In total, 3015 interviews were conducted,
with a participation rate (completed inter-
views/initial sample) of 71.7%. The
response rates were similar in the three
surveys (73.0%, 73.6% and 71.7%).
Use of CAMs
In the 2004 representative population sam-
ple, 52.2% (n = 1574) of the sample said
they had used a CAM over the past year.
CAM use was greatest in women, individu-
als with post-secondary school education, in
the 25–44-year age bracket, respondents
with household income over $30 000, those
who live in the metropolitan area, and in
those who were born in Australia (Box 1).
Lower use was reported for those older than
65 years, separated or divorced, with no
post-secondary school education, and those
who lived in a household with incomes
totalling less than $30 000.
Respondents reported self-prescribed
vitamins as the most used (39.2% of all
respondents), followed by herbal medicines
(20.6%) and mineral supplements (13.6%).
Aromatherapy (11.2%) was the only other
category mentioned by more than 5% of the
sample (Box 2).
Longitudinal comparison with similar
studies2,3 carried out in 1993 and 2000
showed a strong consistency among the total
CAM use in South Australia (50% in 1993,
52.1% in 1993 and 52.2% in 2004) (Box 2).
The use of herbal medicine has risen in both
men and women, with women’s use increas-
ing from 16.6% of female respondents in
2000 to 24.9% in 2004 (χ2 = 35.1; P < 0.01).
1 CAM users by demographic 
variables
n % (95% CI)
Age (years)
15–24 263 53.0% (48.3%–57.7%)
25–34 296 59.9% (55.2%–64.5%)
35–44 318 57.5% (53.0%–61.9%)
45–54 284 54.5% (49.9%–59.0%)
55–64 209 52.4% (47.1%–57.6%)
 65 204 37.0% (32.8%–41.4%)
Sex
Male 679 45.9% (43.2%–48.6%)
Female 896 58.4% (55.7%–60.9%)
Country of birth
Australia 1202 53.6% (51.4%–55.8%)




Asian country 46 45.1% (34.9%–55.8%)









Widowed 375 51.7% (47.8%–55.6%)
Post-secondary school education
No 707 46.1% (43.5%–48.7%)
Yes 868 58.6% (55.9%–61.3%)
Household income (AUD$)




> $80 000 367 60.9% (56.5%–64.8%)
Not stated 156 47.3% (41.7%–52.7%)
Area
Metro 1145 54.2% (51.9%–56.4%)
Country 429 47.6% (44.1%–51.0%)
OVERALL 1574 52.2% (50.3%–54.1%)
Statistically significant differences between CAM 
users and non-users are highlighted (P < 0.05). ◆
2 Longitudinal comparison of the use 
of CAMs 
1993 2000 2004
Vitamins* Total 37.6% 36.4% 39.2%
Males 33.8% 31.5% 35.6%
Females 41.2% 41.2% 42.7%
Herbal 
medicines
Total 9.9% 13.4% 20.6%
Males 8.6% 10.3% 16.1%
Females 11.1% 16.6% 24.9%
Mineral 
supplements
Total 9.2% 10.6% 13.6%
Males 8.1% 9.6% 11.2%
Females 10.3% 11.5% 16.0%
Aromatherapy 
oils
Total 3.5% 15.3% 11.2%
Males 1.9% 8.2% 5.4%
Females 5.2% 22.2% 16.7%
Soy products Total — — 3.8%
Males — — 2.3%
Females — — 5.2%
Chinese 
medicines
Total 1.8% 3.2% 2.3%
Males 1.6% 2.6% 2.0%
Females 2.1% 3.7% 2.7%
Homeopathic 
medicines
Total 4.4% 4.3% 2.2%
Males 3.2% 3.2% 1.5%
Females 5.5% 5.2% 2.9%
Other Total 15.8% 11.3% 6.1%
Males 9.9% 9.3% 5.5%
Females 21.5% 13.3% 6.7%
Total CAM 
users (at least 
one product)
Total 48.5% 52.1% 52.2%
Males 42.0% 43.9% 45.9%
Females 54.8% 60.0% 58.4%
* Not calcium, iron or vitamins prescribed by a 
doctor. Shaded rows are significant at P < 0.05 by χ2 
test. ◆28 MJA • Volume 184 Number 1 • 2 January 2006
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The primary reason for using CAMs was for
general health (Box 3). The reasons for use of
CAMs differed with age, marital status and
education. For example, use of CAMs for
blood or circulation and muscles, bones or joints
increased with age, whereas use for the
immune system decreased with age; those
who had never married had a higher use of
CAMs for the immune system (23.3%); those
who were separated or divorced had higher
use for nerves or stress (27.3%); and those
who had completed a bachelor degree or
higher had a higher use of CAM products for
both general health (77.7%) and the immune
system (25.7%), and a lower use for muscles,
bones and joints (13.6%).
Cost of CAMs
The mean expenditure reported by all CAM
users on the cost of CAM per month was
$21.23 (range, $1 to $650 per month).
Women spent significantly more on CAM
per month ($23.24) than men did ($18.50)
(t = 2.5, df = 1248, P < 0.01). The extrapo-
lated expenditure for the Australian public
in 1993, 2000 and 2004 is shown in Box 4.
There has been a reduction in total expendi-
ture on CAMs since 2000, from $1671
million to $1308 million.
Use of CAM therapists
The use of CAM therapists in the three
surveys is shown in Box 5. In the past year,
26.5% of respondents had visited at least
one CAM therapist. Chiropractors were the
most commonly used CAM therapist.
Women (29.3%) used CAM therapists more
often than men did (23.6%) (χ2 = 12.6,
P < 0.01). With the exception of herbal ther-
apists and “other”, there has been no escala-
tion in the use of CAM therapists since
2000.
Use of CAM therapists peaked in the
middle age brackets (35–44 years, 31.6%;
45–54 years, 32.6%) and tailed off at either
end of the age spectrum (under 25 years,
25.8%; over 65 years, 16.5%). Use was
higher in country areas (29.4%) than metro-
politan areas (25.3%). High use of CAM
therapists was reported by respondents
born in Australia (28.7%). Low use was
reported for those who left school before the
age of 15 years (17.2%). Use also increased
as household income increased, with indi-
viduals reporting an annual income up to
$12 000 using them substantially less than
those reporting an income greater than
$80 000 per annum (17.2% compared with
31.5%; χ2 = 16.3, P < 0.01).
Cost of CAM therapists visited
The mean annual expenditure on CAM ther-
apists was AUD$225 (range, $5 to $5000
per year). The extrapolated Australian
expenditure for CAM therapists and the
total cost of CAM in 1993, 2000 and 2004 is
shown in Box 4. The cost of CAM therapists
in 2004 has decreased since 2000, from
$616 million to $494 million.
General practitioner awareness 
of CAMs used
Respondents who had used CAMs in the
preceding year were asked whether their
general practitioner knew — 53.2% were
taking these products without their GP’s
knowledge. This is consistent with the 2000
survey, which found that 57.2% of users did
not report their use. In the current survey,
women (47.8%) were more likely to tell
their GPs than men were (36.4%) (χ2 = 20.5,
P < 0.01).
Using CAM products and conventional 
medicines
Respondents who had used CAMs in the
preceding year were asked if they had used
them along with conventional medicines on
the same day. About half (49.7%) of those
who had used CAMs had taken them on the
same day as conventional medicines. This
practice was more common in metropolitan
areas (51.6%) than in country areas
(44.6%). It was also more common with
widowed respondents (76.9%); women
(52.4%); those who left school before 15
years of age (65.6%); low-income respond-
ents (up to $12 000, 68.1%; $12 000–
$20 000, 64.3%); and older respondents
(55–64 years, 69.8%; over 65 years, 80%).
Paediatric CAM use
All respondents were asked about the use of
CAM products and therapies by children in
the household. Most households were with-
out children (68.5%). In the households
with children (n = 659), 30.6% of those said
that children in their household had used
CAMs or CAM therapists. Of these, 66.7%
(n = 194) had given their children non-pre-
scribed vitamins, 29.9% (n = 87) had given
their children other specified CAMs, and
17.5% (n = 51) of respondents had children
who had visited a CAM therapist.
Perception of testing of CAMs
About half (48.8%) of the total sample
believed (erroneously) that CAMs are inde-
pendently tested by a government agency
such as the Therapeutic Goods Administra-
tion (TGA) before being sold. This belief was
held by a relatively higher proportion of
people younger than 35 years (55.0%) and a
correspondingly lower proportion of people
older than 55 years (42.6%). Respondents
who had completed a certificate or diploma
(52.5%) were more likely to consider that
these products had been tested independ-
ently. Respondents in the lower income
brackets (up to $12 000, 42.3%; $12 000–
$20 000, 43.5%) were less likely to think
these products had been independently
tested.
The 1471 respondents who believed that
CAMs are independently tested by a govern-
ment agency were further asked to state
what they believed were the nature of these
tests. Most (74.8%) believed that these
4 Extrapolated cost of CAMs and 



















3 Reasons given for using CAMs
Male Female All
General health 68.7% 71.1% 70.1%
Muscles, bones or 
joints
21.6% 20.3% 20.9%
Immune system 18.9% 17.7% 18.2%




PMS/menopause — 14.8% 8.4%
Skin 6.0% 9.6% 8.1%
Lung or sinuses 6.4% 5.5% 5.9%
Stomach or bowel 3.2% 6.9% 5.3%
Bladder or kidneys 1.5% 3.2% 2.5%
Prostate 2.9% — 1.3%
Other 10.3% 12.1% 11.3%
Don’t know 1.6% 0.6% 1.0%
Multiple responses allowed. Significant differences 
(P < 0.05) between sexes are shaded. ◆MJA • Volume 184 Number 1 • 2 January 2006 29
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effects; 21.8% believed that these products
were tested for what they claimed to do, and
17.9% for efficacy/strength/effect.
Quality of life
All 3015 respondents completed the SF36
quality-of-life questionnaire. CAM users
scored significantly lower (P < 0.05) than
non-users in all dimensions except physical
functioning.
DISCUSSION
This third representative population survey
of CAM use shows that in 2004 half the
South Australian population used CAMs
and more than a quarter visited CAM thera-
pists. This survey raises a number of inter-
esting observations and important concerns,
among them that most survey respondents
incorrectly assumed that the TGA had
audited the efficacy and safety of comple-
mentary medicines.
Although there were no significant
changes in the numbers of respondents who
use CAMs since 2000, in 2004 there was a
significant increase in the number of women
compared with men using herbal medicines.
As confirmed in multivariate analyses in our
previous surveys, the greatest users of CAMs
are better-educated, higher income, women
in the 25–44 years age group living in a
metropolitan area. Self-prescribed vitamins
were the most used products, followed by
herbal medicines. Most respondents had no
specific medical reason for using CAMs, but
believed they would help their general
health. Younger respondents were more li-
able to believe that CAMs helped their
immune system and older respondents used
them more often for chronic disabilities
such as joint pains or circulation problems.
Women often try herbal medicines around
their menopause.5 For the first time, we
asked about children’s use of CAMs —
almost a third of respondents with children
had administered CAMs to their children.
In 2004, the overall extrapolated expend-
iture in Australia on complementary medi-
cines from our data decreased to $1.31
billion from $1.67 billion in 2000. However,
as there was little change in the numbers
using CAMs and as, in general, there was
little change in the cost of the commonly
used products, it is likely that CAM users are
now using fewer CAMs per person than in
2000.
This decline in the market could be con-
tributed to consumer response to the
adverse publicity in the media surrounding
CAMs in 2003 during the Pan Pharmaceuti-
cal crisis. In 2003, the TGA had serious
concerns about the content and quality con-
trol of products manufactured by Pan Phar-
maceuticals. After an audit prompted by a
range of hospitalisations and other serious
adverse events to an over-the-counter non-
CAM product manufactured by the com-
pany, the TGA suspended the company’s
licence to manufacture, and required the
recall of 1600 products — mostly CAMs. It
has been estimated that this company man-
ufactured about 40% of CAMs on the Aus-
tralian market. The suspension of its licence
resulted in a substantial quantity of CAMs
being removed from retail outlets, which
may have interrupted or reduced respond-
ents’ use of CAMs.
A similar effect was seen in the use of
menopausal hormone replacement therapies
in 2002 when media reported, and often
exaggerated, the risks of long-term therapy
with one regimen.6 Hormone therapy use
dropped to a third of its prior use, but has
since returned to two-thirds of the levels of
use recorded before 2002. Thus, the media
appears to have a great influence on deci-
sion-making regarding both conventional
and complementary medication.
In contrast to the decline in use of CAMs,
there has been a steady increase in use of
CAM therapists by the South Australian
public over the past 10 years. Chiropractors,
followed by naturopaths, were the most
frequently visited. The profile of the most
common user was a woman, between the
ages of 35 and 44 years, living in the
country, with a higher than average income
level. There was a wide range of expenditure
on CAM therapists but, again, overall aver-
age costs since 2000 had decreased (by
20%), suggesting a lower frequency of
attendance.
It is of continuing concern that about half
of CAM users ingested them on the same day
as conventional medicines and that more
than half (53.2%) did not tell the doctor
prescribing conventional medicines that they
were also taking CAMs. This is a critical issue
that needs to be addressed to ensure that the
use of CAMs by the community is consistent
with the National Strategy for Quality Use of
Medicines. Interactions between some CAMs
and some prescribed medicines have been
frequently described.7,8 Yet, lay beliefs are
that most CAMs are safe.3 This is in contrast
to increasing reports of adverse effects from
CAMs9,10 and other problems seen predomi-
nantly overseas, such as contamination,
adulteration, substitution, variable dosage,
dubious quality control and inappropriate
labelling.10,11 Doctors need to directly ask
about the use of CAMs in a non-judgmental
manner to better ascertain the risks of drug
interactions and potential side effects from
CAMs.
Giving children medicines that have not
been tested in children is another important
quality use of medicines concern. In house-
holds we surveyed where there were children
under the age of 15 years, a third of these
children had been administered CAMs. Other
surveys have reported use of CAM therapies
during pregnancy and in our last survey only
36.2% of respondents thought that CAMs
were not safe during pregnancy.3 Although
few CAMs have been shown to be tera-
togenic, most have not been sufficiently
tested to rule out adverse fetal effects and
CAMs should not be used during pregnancy.
Users of CAMs had a lower quality of life
in all of the physical and psychological
5 Use of CAM therapists in 1993, 2000 and 2004
1993 2000 2004
Total Total Male Female Total
Chiropractor 15.0% 16.7% 16.1% 17.3% 16.7%
Naturopath/Natural Therapist 5.0% 6.0% 3.6% 7.6% 5.7%
Acupuncturist 2.0% 2.8% 1.2% 3.1% 2.1%
Homeopath 1.2% 1.2% 0.1% 0.9% 0.5%
Iridologist 0.8% 1.2% 0.2% 1.4% 0.8%
Reflexologist 0.7% 1.2% 1.2% 0.8% 1.0%
Aromatherapist 0.6% 1.3% 0.6% 1.5% 1.1%
Herbal therapist 0.4% 0.9% 1.0% 1.5% 1.9%
Osteopath 0.2% 0.4% 0.4% 0.4% 0.4%
Other 1.8% 1.2% 3.9% 5.6% 4.8%
Total (any visited) 20.3% 23.3% 23.6% 29.3% 26.5%30 MJA • Volume 184 Number 1 • 2 January 2006
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physical functioning. However, these results
should be interpreted with caution as this
was a cross-sectional study and longitudinal
quality-of-life scores are not available from
before self-medication with CAMs began. In
some cases the public, particularly older
respondents, are using CAMs because of
chronic health problems and thus they may
have had low quality-of-life scores before
starting medication. Also, surveys are open
to recall bias and potential bias if non-
respondents differ from the respondents.
However, response rates were high in all
three of our surveys and on retesting 10% of
respondents the answers remained consist-
ent.
It has been argued that the rising use of
CAMs does not change the rules for
informed consent.12 If a physician or CAM
therapist advocates or prescribes CAMs then
it is their legal duty to warn the patient of:
• the material hazards,
• possible complications that could occur,
• reasonable alternatives, and
• the effects of non-treatment.
Prescribers must also have a thorough
knowledge of the patient’s medical history,
pertinent family history, current medications
and risk of pregnancy. This responsibility is
incumbent even on those who advise on
CAMs at the point of sale; however, most
CAMs are not sold with general product
information to alert the consumer to possi-
ble risks. Further, the scientific evidence
that underpins the role of CAMs for the
broad range of conditions for which they are
used is far from complete. The quality of the
evidence for specific CAM medicines or
interventions for specific medical conditions
ranges from first class to nonexistent.13-17
Even in areas where a substantive amount of
work has been undertaken, the research
suffers from a lack of methodological rigour.
The Chairman of the Australian Health
Ethics Committee, National Health and
Medical Research Council, has argued the
ethics of promoting products or therapies
that may only have a placebo effect.18 Those
who practise or recommend CAM have ethi-
cal responsibilities to inform patients when
the therapy is unproven as well as of any
potential risks. Patients offered CAM inter-
ventions must not be denied access to stand-
ard proven therapies. Equally, as the
evidence base for CAM increases, any CAM
medicine or intervention with appropriate
evidence should be seen as a reasonable
alternative to a conventional medical
approach.
Our results clearly showed that half the
population thought that CAMs were inde-
pendently tested by the TGA before being
allowed to be sold. Currently, the TGA has
limited capacity (as the nature of TGA fund-
ing requires full cost recovery) and audits
less than 1% of CAMs on the market. Most
CAMs are “Listed” (L classification) by the
TGA on the Australian Register of Therapeu-
tic Goods (their stated contents and safe
manufacture have been accepted without
audit and without proof of efficacy) and can
be sold and advertised with “low level”
claims. In contrast, “Registered” (R classifi-
cation) medicines have been assessed for
quality, safety and efficacy.
The Expert Committee on Complemen-
tary Medicines in the Australian Health Sys-
tem, set up by the Australian Government
after the Pan Pharmaceutical crisis, recom-
mended an increase in the random and
targeted assessment of the indications and
claims held by sponsors of CAMs.19 The
committee made 49 major recommenda-
tions for improved regulation of comple-
mentary medicines in Australia. In 2005,
the Australian Government accepted all but
one of these recommendations and is now
implementing the process. These changes
will strengthen the regulatory framework for
CAMs and CAM therapists in Australia.
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